April 18, 2022 7:30am

What goes … as future aren’t much help as the sector and market suffered further losses last week and not looking up this new Monday

Pre-open indications: 5 Possible BUYs, 3 Potential SELLs and 1 Pimp/Pump/Promote

RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Just the facts … I ask questions and note the indications of what could happen …


Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.


Dow futures are DOWN -0.03% (-10 points), S&P futures are DOWN -0.15% (-6 points) and NASDAQ futures are DOWN -0.20% (-28 points) early in the pre-open


Stock futures declined early in Monday’s pre-open after last week’s losses and shortened week,

European stocks closed inching higher as some markets in Europe were closed,

Asia-Pacific stocks were closed in Australia and Hong Kong was closed on Monday.

mostly higher on Thursday as investors reacted to monetary policy tightening announcements by central banks in South Korea and Singapore.



Last Thursday, the Dow was down -113.36 or -0.33%, the S&P dipped 54 points or -1.21% while the Nasdaq dived 292.51 or -2.14%.

For me, I am shut-in as the Boston Marathon begins just down the street, the state police helicopters are buzzing around as the town of Hopkinton, Mass was being shut-down at 6:30 a.m.


Last night’s RegMed Investors’ (RMi) closing bell post: “closing with a downslide shortened week with Friday market holiday. The cell and gene therapy sector slipped into another share pricing abyss after I wrote “curb your enthusiasm” and skim in anticipation of a coming depreciation.” …  https://www.regmedinvestors.com/articles/12389

Ebb and flow –

Q2/22 –1 holiday, 3 positive and 7 negative close


·         March – 13 negative and 10 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes


Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS


Agenus (AGRN) with a positive pre-open indication +$0.02 or +0.85%

AxoGen (AGNX) with a positive pre-open indication +$0.50 or +6.90%

AVROBIO (AVRO)with a positive pre-open indication +$0.03 or +0.85%

Beam Therapeutics (BEAM) with a positive pre-open indication +$0.05 or +0.11%

uniQure NV (QURE) with a positive +$0.05 or +0.27% pre-open indication.



CRISPR Therapeutics (CRSP) with a negative -$0.59 or -0.95% pre-open indication.

Fate Therapeutics (FATE) with a negative -$0.77 or -2.04% pre-open indication.

Voyager Therapeutics (VYGR) with a negative -$0.02 or -0.22% pre-open indication.


Pimp/Pump and Promote:

Biostage (BSTG) closed down Thursday -$0.02 to $5.98 after Wednesday ’s  +$0.50 with 2,851 shares traded after Tuesday’s -$0.30 with 1,634 shares traded and last Monday’s flat with 25 shares traded,.

  • WARNING:  WHY BUY this equity with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a precarious financial position dependent on a possible cash infusion? Also, WHY the pump of the volume to gain share appreciation – they have to reverse the multiple private placements (the priciest was $4.71) for a potential/proposed stock offering.


The BOTTOM LINE: State the obvious, investors are NOT in control of daily market driven sector appreciation or downward dives.

I try to keep it simple … and short!

To expect a payday; volatility and low volume are part of the equation.

I am still, in the here and now, the cell and gene therapy sector will be on hold until clinical results stimulate these equities!

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.


Share pricing intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider their investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.